← Product Code [OQZ](/submissions/IM/subpart-f%E2%80%94immunological-test-systems/OQZ) · K092399

# ANTI-MUTATED CITRULLINATED VIMENTIN EIA (K092399)

_Orgentec Diagnostika GmbH · OQZ · Jul 1, 2010 · Immunology · SESE_

**Canonical URL:** https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/OQZ/K092399

## Device Facts

- **Applicant:** Orgentec Diagnostika GmbH
- **Product Code:** [OQZ](/submissions/IM/subpart-f%E2%80%94immunological-test-systems/OQZ.md)
- **Decision Date:** Jul 1, 2010
- **Decision:** SESE
- **Submission Type:** Traditional
- **Regulation:** 21 CFR 866.5775
- **Device Class:** Class 2
- **Review Panel:** Immunology

## Indications for Use

Anti-MCV® is an indirect solid phase enzyme immunoassay (ELISA) for the qualitative and semi-quantitative measurement of IgG class autoantibodies against mutated citrullinated vimentin (MCV) in human serum. The assay is intended for in vitro diagnostic use only as an aid in the diagnosis of Rheumatoid Arthritis (RA) in conjunction with other laboratory and clinical findings.

## Device Story

Indirect solid phase ELISA; detects IgG autoantibodies against mutated citrullinated vimentin (MCV) in human serum. Device components: microplate coated with MCV antigen; calibrators; controls; sample buffer; HRP-conjugated anti-human IgG; TMB substrate; stop solution. Procedure: patient serum diluted in buffer added to MCV-coated wells; patient antibodies bind to antigen; washing removes unbound components; HRP-conjugated anti-human IgG added to form conjugate/antibody/antigen complex; washing removes unbound conjugate; TMB substrate added; enzymatic reaction produces blue color; acid stop solution turns product yellow. Intensity measured photometrically at 450 nm; color intensity proportional to IgG concentration. Used in clinical laboratories by trained personnel. Output: qualitative (positive/negative) and semi-quantitative (U/mL) results. Assists clinicians in diagnosing Rheumatoid Arthritis.

## Clinical Evidence

Clinical study evaluated 1,246 samples: 490 clinically diagnosed Rheumatoid Arthritis (RA) patients and 756 non-RA disease/normal controls. Clinical sensitivity was 81.2% (95% CI 77.8–84.7%) and clinical specificity was 98.0% (95% CI 96.7–98.9%). Method comparison with predicate (n=555) showed 96.6% overall agreement. Analytical performance included intra-assay (CV 5.3-10.2%), inter-assay (CV 4.6-15.3%), and inter-lot precision (CV 1.5-18.4%).

## Technological Characteristics

Indirect solid-phase ELISA. Components: microplate, 6 calibrators, positive/negative controls, enzyme conjugate, sample buffer, TMB substrate, hydrochloric acid stop solution, wash buffer. Analyte: IgG autoantibodies against mutated citrullinated vimentin. Detection: colorimetric via TMB substrate. Measuring range: 3.0 to 900 U/mL. Storage: 2-8°C. Sample: human serum. Connectivity: none (standalone).

## Regulatory Identification

A rheumatoid factor immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the rheumatoid factor (antibodies to immunoglobulins) in serum, other body fluids, and tissues. Measurement of rheumatoid factor may aid in the diagnosis of rheumatoid arthritis.

## Predicate Devices

- Immunoscan RA anti-CCP Test Kit ([K052133](/device/K052133.md))

## Submission Summary (Full Text)

> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).

{0}

1

# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number:
k092399

B. Purpose for Submission:
New device

C. Measurand:
Anti-mutated Citrullinated Vimentin IgG

D. Type of Test:
Semi-quantitative and qualitative ELISA

E. Applicant:
ORGENTEC Diagnostika GmbH

F. Proprietary and Established Names:
Anti-mutated Citrullinated Vimentin IgG EIA

G. Regulatory Information:
1. Regulation section
21 CFR § 866.5775 – Rheumatoid factor immunological test system
2. Classification
Class II
3. Product code
OQZ, Anti-mutated Citrullinated Vimentin IgG
4. Panel
Immunology (82)

H. Intended Use:
1. Intended use(s)
Anti-MCV® IgG EIA is an indirect solid phase enzyme immunoassay (ELISA) for the qualitative and semi-quantitative measurement of IgG class autoantibodies against mutated citrullinated vimentin (MCV) in human serum.
2. Indication(s) for use:
The assay is intended for in vitro diagnostic use only as an aid in the diagnosis of Rheumatoid Arthritis in conjunction with other laboratory and clinical findings.
3. Special conditions for use statement(s)
For prescription use only
4. Special instrument requirements
ELISA plate reader at 450 nm

I. Device Description:
Each Anti-MCV® EIA Kit contains the following components:
1. Divisible microplate consisting of 12 modules of 8 wells each, coated with mutated citrullinated Vimentin (MCV).
2. Calibrators with Anti-MCV® IgG antibodies (A-F) in a serum/buffer matrix (PBS, BSA, NaN₃ < 0.1% (w/w)): 0; 20; 40; 100; 300; and 1000 U/mL.
3. Anti-MCV positive and negative controls in a serum/buffer matrix (PBS, BSA,

{1}

$\mathrm{NaN}_3 < 0.1\%$  (w/w)) one vial (1.5 mL). Ready to use.

4. Sample buffer (Tris,  $\mathrm{NaN}_3 < 0.1\%$  (w/w)), yellow, concentrate (5x). 1 vial,  $20~\mathrm{mL}$
5. Enzyme conjugate solution (PBS, Proclin  $300 < 0.5\%$  (v/v)), (light red) containing polyclonal rabbit anti-human IgG; labeled with horseradish peroxidase.
5. TMB substrate solution.
6. Stop solution (contains acid).
7. Wash solution (PBS,  $\mathrm{NaN}_3 < 0.1\%$  (w/w)), concentrate (50x).

# J. Substantial Equivalence Information:

1. Predicate device name(s): Eurodiagnostica Immunoscan Anti-CCP (Cyclic Citrullinated Peptide) IgG Antibody Test
2. Predicate 510(k) number(s): k052133
3. Comparison with predicate:

|  Similarities  |   |   |
| --- | --- | --- |
|  Item | Predicate | Device  |
|   | Immunoscan RA Anti-CCP | ORGENTEC Anti-MCV  |
|  Indication for use | Aid in the diagnosis of Rheumatoid Arthritis (RA) in conjunction with other laboratory and clinical findings. | Same  |
|  Method | ELISA | Same  |
|  Solid phase | Microwells | Same  |
|  Controls | Negative control Positive control | Same  |
|  Sample matrix | human serum or plasma | Same  |
|  Test results | Qualitative and Semi-Quantitative | Same  |
|  Storage | 2-8°C (35 - 46°F) | Same  |
|  Conjugated antibody | Horse Radish Peroxidase (HRP) labeled polyclonal anti-human IgG | Same  |
|  Type of substrate | TMB (3,3',5,5'-Tetramethyl-benzidine) | Same  |
|  Open Vial stability | 30 days | Same  |
|  Differences  |   |   |
| --- | --- | --- |
|  Item | Predicate | Device  |
|  Analyte | Anti-CCP | Anti-MCV  |
|  Antigen | Cyclic citrullinated peptide | Mutated citrullinated vimentin  |
|  Sample dilution factor | 1:100 | 1:50  |

{2}

|  Differences  |   |   |
| --- | --- | --- |
|  Item | Predicate | Device  |
|  Total incubation time | 60 minutes at room temperature (18-28°C) | 120 minutes at room temperature (18-25°C)  |
|  Cut-off | ≥ 25 U/mL | ≥ 20 U/mL  |
|  Calibrator | Anti-CCP IgG calibrators (25; 50; 200; 800; and 1600 U/mL) | Anti-MCV IgG calibrators (0; 20; 40; 100; 300; and 1000 U/mL)  |

# K. Standard/Guidance Document Referenced (if applicable):

Not applicable

# L. Test Principle:

Anti-MCV® IgG EIA is an indirect solid phase enzyme immunoassay. Mutated citrullinated vimentin (MCV) is bound to microwells. Antibodies against this antigen, if present in diluted serum or plasma, bind to the respective antigen. Washing of the micro- wells removes unspecific serum and plasma components. Horseradish peroxidase (HRP) conjugated anti-human IgG immunologically detects the bound patient antibodies forming a conjugate/antibody/antigen complex. Washing of the microwells removes unbound conjugate. An enzyme substrate in the presence of bound conjugate hydrolyzes to form a blue color. The addition of an acid stops the reaction forming a yellow end-product. The intensity of this yellow color is measured photometrically at  $450~\mathrm{nm}$ . The amount of color is directly proportional to the concentration of IgG antibodies present in the original sample.

# M. Performance Characteristics (if/when applicable):

# 1. Analytical performance:

# a. Precision/Reproducibility:

Statistics for Coefficients of Variation (CV) were calculated for each of seven samples from the results of 16 determinations in a single run for Intra-Assay precision. The set of same 7 specimens were used for the intra- and inter-assay imprecision studies. Run-to-run precision was calculated from the results obtained by one operator for 5 different runs performed on 5 different days with single determinations of each sample. The acceptance criteria are the imprecision should be less than  $15\%$ .

Table 1. Intra-assay Precision

|  Intra-Assay Precision  |   |   |   |   |
| --- | --- | --- | --- | --- |
|  Sample | n | Mean [U/mL] | SD | CV [%]  |
|  1 | 20 | 3.2 | 0.32 | 10.2  |
|  2 | 20 | 21.8 | 1.47 | 6.7  |
|  3 | 20 | 17.3 | 1.1 | 6.3  |
|  4 | 16 | 20.2 | 1.1 | 5.3  |
|  5 | 16 | 111.0 | 10.2 | 9.2  |
|  6 | 16 | 451.6 | 34.8 | 7.7  |
|  7 | 16 | 806.2 | 73.1 | 9.1  |

{3}

Table 2. Inter-assay Precision

|  Inter-Assay Precision  |   |   |   |
| --- | --- | --- | --- |
|  Sample | Mean [U/mL] | SD | CV [%]  |
|  1 | 5.0 | 0.76 | 15.3  |
|  2 | 20.1 | 2.9 | 14.2  |
|  3 | 22.7 | 1.4 | 6.2  |
|  4 | 27.0 | 3.7 | 13.6  |
|  5 | 118.8 | 7.6 | 6.4  |
|  6 | 548.1 | 25.1 | 4.6  |
|  7 | 981.5 | 68.7 | 7.0  |

Inter-Lot precision was calculated from the results of four different kit lots with single determinations using twelve samples.

Table 3. Inter-lot Precision

|  Inter-Lot  |   |   |   |
| --- | --- | --- | --- |
|  Sample | Mean [U/mL] | SD | CV [%]  |
|  1 | 6.9 | 0.9 | 13.0  |
|  2 | 17.2 | 2.5 | 14.4  |
|  3 | 20.4 | 1.7 | 8.4  |
|  4 | 21.9 | 2.2 | 10.2  |
|  5 | 27.6 | 2.0 | 7.4  |
|  6 | 130.4 | 17.1 | 13.1  |
|  7 | 150.3 | 7.8 | 5.2  |
|  8 | 255.1 | 9.4 | 3.7  |
|  9 | 255.7 | 27.1 | 10.6  |
|  10 | 327.0 | 4.8 | 1.5  |
|  11 | 652.2 | 120.3 | 18.4  |
|  12 | 1043.2 | 17.3 | 1.7  |

Inter-Laboratory precision was calculated for each of twenty-two samples tested in single determination with one lot by three individuals in three different laboratories. Results are shown in the below tables.

Table 4. Inter-laboratory Precision

|  Inter-Laboratory  |   |   |   |
| --- | --- | --- | --- |
|  Sample No. | Mean [U/mL] | SD | CV [%]  |
|  1 | 4.6 | 0.5 | 11.2  |
|  2 | 6.9 | 1.0 | 14.5  |
|  3 | 4.1 | 0.6 | 13.3  |
|  4 | 5.5 | 0.8 | 14.9  |
|  5 | 19.9 | 0.6 | 2.8  |
|  6 | 18.5 | 0.6 | 3.1  |
|  7 | 39.5 | 4.0 | 10.2  |
|  8 | 37.3 | 3.8 | 10.2  |
|  9 | 78.4 | 3.8 | 4.8  |
|  10 | 73.3 | 2.5 | 3.4  |
|  11 | 141.6 | 2.9 | 2.8  |

{4}

5

|  Inter-Laboratory  |   |   |   |
| --- | --- | --- | --- |
|  Sample No. | Mean [U/mL] | SD | CV [%]  |
|  12 | 138.7 | 3.8 | 2.7  |
|  13 | 173.8 | 8.0 | 4.6  |
|  14 | 171.8 | 18.4 | 10.7  |
|  15 | 234.6 | 17.3 | 7.4  |
|  16 | 242.4 | 28.7 | 11.8  |
|  17 | 222.4 | 20.9 | 9.4  |
|  18 | 214.1 | 17.0 | 7.9  |
|  19 | 266.6 | 21.8 | 8.2  |
|  20 | 245.4 | 5.6 | 2.3  |
|  21 | 487.1 | 11.9 | 2.4  |
|  22 | 538.3 | 69.1 | 12.8  |

The specification for acceptance is $\mathrm{CV} = < 15\%$. The specification was met.

b. Linearity/assay reportable range:

Four patient samples containing high levels of antibody were serially diluted 6-9 times in buffer throughout the dynamic range of the assay to demonstrate the upper end of linearity. Specifications are that linear regression coefficient $(\mathbb{R}^2)$ should be $\geq 0.990$ and recovery is $100\% \pm 20\%$. Results met the criteria and were considered linear. The calculated values together with the recovery and the linear regression coefficient $(\mathbb{R}^2)$ are shown in the table below.

Table 5. Summary of Linearity

|   | Sample 1 | Sample 2 | Sample 3 | Sample 4  |
| --- | --- | --- | --- | --- |
|  Concentration U/mL | 882.8 | 932.1 | 727.9 | 901.3  |
|  Regression R² | 0.9963 | 0.9993 | 0.9999 | 0.9971  |
|  Average % Recovery | 90 | 102 | 97 | 106  |
|  Range of % Recovery | 81-100 | 93-109 | 84-100 | 93-108  |

Reportable range

3.2-900 U/mL

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Traceability:

There is no reference standard for anti-MCV. The values for calibrators (A-F) and controls (C1 and C2) are arbitrary units.

Reagent stability

Each kit lot produced by ORGENTEC is tested throughout its complete shelf life. The data presented in the stability studies derives from the stability testing of three random kit lots. The assay kit was stable for 18 months under $2 - 8^{\circ}\mathrm{C}$. The diluted sample buffer and wash buffer are stable for at least 30 days when stored at $2 - 8^{\circ}\mathrm{C}$.

Sample stability

Twelve samples with anti-MCV concentrations ranging from 17.6 to 959.7 U/mL were tested in duplicate to determine stability of storage at $2 - 8^{\circ}\mathrm{C}$ for 5 days. Results met acceptance criteria with $\%$ recovery ranged from $94\%$ to

{5}

100%.

d. Detection limit:

i. Limit of Blank (loB)

Sample Buffer was diluted according to instructions for use and measured 32 times on one plate. Calibrators and Controls were analyzed in duplicate. The detection limit was calculated as the mean of the optical densities (OD) of the Sample Buffer plus 3 SD and expressed in U/mL. Acceptance Criteria: The analytical sensitivity has to be ≤ 1 U/mL. The (mean + 3 SD) was 0.044 OD for the Sample Buffer, which corresponded to an analytical sensitivity of 0.6 U/mL.

ii. Limit of Detection (LoD)

The limit of detection was calculated from LoB and LoQ using the following formula  $\mathrm{LoD} = \mu \mathrm{B} + 1.645\delta \mathrm{B} + 1.645\delta \mathrm{S}$ . (Note: B = Blank; S = Lowest Sample).

The LOD = 0.032OD Mean of Blank + 1.645x 0.007OD (0.012OD) = 0.044OD = 3.0 U/mL.

iii. Limit of Quantitation (LoQ)

Limit of quantitation was determined from the coefficient of variation of four very low serum samples run in replicates of 16 in three assay runs. The lowest concentration which could be measured with a coefficient of variation below  $20\%$  is  $3.2\mathrm{U / mL}$ .

e. Analytical specificity:

i. Interference

Interference due to bilirubin, hemoglobin and lipemia was evaluated using a negative serum, a low positive serum and a high positive serum spiked with the respective interfering substance in increasing concentrations. Hemoglobin up to  $1000\mathrm{mg / dL}$ , bilirubin up to 40  $\mathrm{mg / dL}$ , and lipemia (i.e. triglyceride concentration) up to  $3000\mathrm{mg / dL}$  in human serum do not interfere with Anti-MCV® ELISA results.

ii. Cross reactivity

A series of patient samples from other potentially cross-reacting and similar symptoms to Rheumatoid Arthritis were evaluated for reactivity in the Anti-MCV® assay. No positive results were found in these samples. The results of the testing are summarized below.

Table 6. Cross-reactivity

|  Condition | Total No. | Positives No. | Positives % | Clinical Specificity %  |
| --- | --- | --- | --- | --- |
|  Blood donors | 443 | 4 | 0.9% | 99.1%  |
|  Psoriasis Arthritis | 10 | 0 | 0.0% | 100.0%  |
|  Juvenile Arthritis | 15 | 0 | 0.0% | 100.0%  |
|  Scleroderma | 8 | 0 | 0.0% | 100.0%  |
|  Sicca Symptomatic | 6 | 0 | 0.0% | 100.0%  |
|  Sjögren Syndrome | 50 | 2 | 4.0% | 96.0%  |
|  UCTD | 25 | 1 | 4.0% | 96.0%  |
|  MCTD | 6 | 0 | 0.0% | 100.0%  |
|  SLE | 97 | 3 | 3.1% | 96.9%  |
|  APS | 20 | 0 | 0.0% | 100.0%  |

{6}

|  Condition | Total No. | Positives No. | Positives % | Clinical Specificity %  |
| --- | --- | --- | --- | --- |
|  Celiac Disease | 75 | 1 | 1.3% | 98.7%  |
|  Morbus Crohn | 1 | 0 | 0.0% | 100.0%  |
|  Microscopic Polyangiitis | 30 | 2 | 6.7% | 93.3%  |
|  Morbus Wegener/Vasculitis | 7 | 0 | 0.0% | 100.0%  |
|  Polymyositis/Dermatomyositis | 3 | 0 | 0.0% | 100.0%  |
|  Thyroiditis | 104 | 3 | 2.9% | 97.1%  |
|  div. Infectious Diseases | 25 | 0 | 0.0% | 100.0%  |
|  Diabetes Mellitus | 40 | 2 | 5.0% | 95.0%  |
|  Non-RA: | 965 | 18 | 1.9% | 98.1%  |

f. Assay cut-off:

Values ≥20 U/mL are considered positive, values < 20 U/mL are considered negative

2. Comparison studies:

a. Method comparison with predicate device:

Five hundred and fifty five (555) sera with concentrations ranged from Anti MCV IgG 1.5 - 900 U/mL were tested by the ORGENTEC Anti-MCV® ELISA in single measurement and by the Immunoscan Anti-CCP IgG ELISA. The quantitative results were calculated from a calibration curve on the basis of tested calibrators. In the ORGENTEC Anti-MCV® assay quantitative values above or equal to 20 U/mL were considered positive, values below 20 U/mL were considered negative. In the Immunoscan Anti-CCP IgG assay quantitative values above or equal 25 U/mL were considered positive, values below 25 U/mL were considered negative.

A summary analysis of the results are shown in the following Tables:

Table 7. A Summary of Data Analysis of the Method Comparison

|  Comparative Method Anti-CCP  |   |   |   |
| --- | --- | --- | --- |
|  ORGENTEC | Positive | Negative | Total  |
|  Positive | 231 | 10 | 241  |
|  Negative | 9 | 305 | 314  |
|  Total | 240 | 315 | 555  |
|  Positive Percent Agreement: | 96.3% | C.I. (95%) = 93.0 – 98.3%  |   |
|  Negative Percent Agreement: | 96.8% | C.I. (95%) = 94.2 – 98.5%  |   |
|  Overall Agreement: | 96.6% | C.I. (95%) = 94.7 – 97.9%  |   |

b. Matrix comparison:

Use human serum only.

3. Clinical studies:

Patient samples were collected from various types of sites and commercial sources that provided known disease characteristics and sufficient number of samples to cover the range of rheumatological and non-rheumatological conditions to demonstrate the performance of this test. Following is a summary of the groups and sources identified for this study.

{7}

# Inclusion criteria

i. Clinically characterized Rheumatoid Arthritis (according to American College of Rheumatology (ACR) criteria) were defined clinically RA-positive
ii. Disease Control characterized non-RA samples from diseases with clinical symptoms similar to RA, grouped as: rheumatological/SLE/other autoimmune disease/non-inflammatory disease samples. They were defined clinically RA-negative.
iii. Negative control group

Healthy individuals (blood donors), grouped "normal". They were defined RA-negative.

# Exclusion criteria

i. Patient with any condition that would prevent participation in the study and completion of the study procedures.
ii. Patient is not willing to sign an informed consent.

Summary of the Anti-MCV IgG frequency distribution among the study subjects

Table 8. Observed Frequencies of Anti-MCV IgG for Disease Group (U/mL)

|   | <0.6 | 0.6 to 3.5 | 3.6 to 15 | 16 to 20 | 21 to 25 | 31 to 40 | 41 to 80 | 81 to 1000 | >1000 | Totals  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  Rheumatoid arthritis | 1 | 10 | 75 | 9 | 24 | 27 | 66 | 201 | 77 | 490  |
|  Rheumatological SLE | 1 | 16 | 93 | 7 | 2 | 0 | 1 | 0 | 0 | 120  |
|  Other autoimmune | 4 | 42 | 184 | 6 | 0 | 1 | 3 | 0 | 0 | 97  |
|  Non-inflammatory | 0 | 12 | 50 | 1 | 0 | 1 | 1 | 0 | 0 | 240  |
|  Normal | 1 | 32 | 191 | 9 | 0 | 1 | 0 | 0 | 0 | 65  |
|  Totals | 8 | 116 | 678 | 36 | 29 | 30 | 71 | 201 | 77 | 1246  |

a. Clinical Sensitivity and Clinical specificity

Studies were performed to evaluate the sensitivity and specificity of the Anti-MCV® (ELISA) test when compared to the predicate assay Anti-CCP IgG assay (Immunoscan, Eurodiagnostica) using a mix of clinically diagnosed Rheumatoid Arthritis disease state samples and a presumed normal asymptomatic blood bank population and other arthritic and autoimmune patient samples obtained from hospital labs and autoimmune clinics.

The sensitivity performance of the ORGENTEC Anti-MCV® assay was established using four hundred and ninety (n=490) samples from clinically diagnosed patients as having Rheumatoid Arthritis disease that were obtained from a variety of clinical sources (hospitals and autoimmune clinics). The patients collectively included 124 males and 366 females. The age ranged from 19 to 92 years. The specificity performance of the ORGENTEC Anti-MCV® assay was established using 234 "presumed normal" sera obtained from blood donor centers age 24 to 82 years, 522 other samples from patients with arthritic and autoimmune disease conditions, obtained from a variety of clinical sources

{8}

(hospitals and autoimmune clinics) age 2 to 92 years. The samples collectively included 166 males and 590 females.

Based on clinical diagnosis, three hundred ninety-eight of the 490 Rheumatoid Arthritis disease diagnosed sera were positive in the ORGENTEC Anti-MCV® assay and ninety-two tested as negative, thus yielding a clinical diagnostic sensitivity of 81.2% (95% CI 77.8 – 84.7%). This data is consistent with reported data of sensitivities ranging from 69% to 82% for commercial Anti-MCV IgG assay for the diagnosis and follow up of RA Disease patients (Table in Egerer et al., Deutsches Ärzteblatt International® Dtsch Arztebl Int 2009; 106 (10):159–63).

The specificity of the ORGENTEC Anti-MCV® assay was 98% (95% CI 96.7 – 98.9%)

A summary of analyses of the results is shown in the following Tables:

Table 9. Summary of Data Analysis of Clinical Studies

|  Clinical Diagnosis  |   |   |   |
| --- | --- | --- | --- |
|  ORGENTEC | Disease | Non-Disease | Total  |
|  Positive | 398 | 15 | 413  |
|  Negative | 92 | 741 | 833  |
|  Total | 490 | 756 | 1246  |
|  Clinical Sensitivity: | 81.2% | C.I. (95%) = 77.8 – 84.7%  |   |
|  Clinical Specificity: | 98.0% | C.I. (95%) = 96.7 – 98.9%  |   |
|  Clinical Agreement: | 91.5% | C.I. (95%) = 89.7 – 92.9%  |   |

On a subset of n=399 specimens for which measurement data of the predicate were available, the assay performance data compared to the clinical diagnosis are summarized in the following Table 10:

Table 10. Assay Performance of the Predicate Compared to Clinical Diagnosis

|  Clinical Diagnosis  |   |   |   |
| --- | --- | --- | --- |
|  Predicate Device | Disease | Non-Disease | Total  |
|  Positive | 239 | 2 | 241  |
|  Negative | 82 | 76 | 158  |
|  Total | 321 | 78 | 399  |
|  Clinical Sensitivity: | 74.5% | C.I. (95%) = 69.7 – 79.2%  |   |
|  Clinical Specificity: | 97.4% | C.I. (95%) = 91.0 – 99.7%  |   |
|  Clinical Agreement: | 78.9% | C.I. (95%) = 74.9 – 82.0%  |   |

b. Other clinical supportive data
None

4. Clinical cut-off:

{9}

Same as assay cut-off.

5. Expected values/Reference range:

A series of 209 assumed normal blood donor samples ages 18 to 69 years were collected from various blood banks. These 209 samples were tested in the

ORGENTEC Anti-MCV® assay to determine a normal range and cut-off for the assay.

The combined mean concentration of Anti-MCV® antibodies was 5.6 U/ml. The mean+2SD was 12.8 U/mL, and mean+3SD = 16.5 U/mL.

Based on these results the cut-off was determined to be ≥ 20 U/ml.

At a cut-off of ≥ 20 U/ml, 1 sample was positive for a specificity of 99.5%.

N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

10

---

**Source:** [https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/OQZ/K092399](https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/OQZ/K092399)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com